CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

Showing 5 of 5 entries

View as:

Phase: N/A Priority: Normal

NCT ID: NCT01386216 Org: User:

Start: 04/30/11 End: 12/31/16 Due: 12/31/17

Phase: N/A Priority: Normal

NCT ID: NCT02169362 Org: User:

Start: 07/31/14 End: 05/31/18 Due: 05/31/19

Phase: N/A Priority: Normal

NCT ID: NCT02071979 Org: User:

Start: 04/30/14 End: - Due: -

Phase: N/A Priority: Normal

NCT ID: NCT01843686 Org: User:

Start: 04/30/13 End: 03/31/18 Due: 03/31/19

Phase: N/A Priority: Normal

NCT ID: NCT01837264 Org: User:

Start: 01/31/13 End: 01/31/17 Due: 01/31/18

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)	NCT01386216	Arteriocyte, Inc.	user2@example.com	None	2011-04-30	2016-12-31	2017-12-31	-	-	2025-07-14
Applying Platelet Rich Plasma (PRP) Gel to Acute Deep Partial Thickness Thermal Injuries	NCT02169362	Arteriocyte, Inc.	user2@example.com	None	2014-07-31	2018-05-31	2019-05-31	-	-	2025-07-14
Registry Trial of the Effectiveness of Platelet Rich Plasma for Chronic Non-Healing Wounds	NCT02071979	Arteriocyte, Inc.	user2@example.com	None	2014-04-30	-	-	-	-	2025-07-14
Using Autologous Platelet Rich Plasma (PRP) Gel to Treat Deep 2nd and 3rd Degree Burns	NCT01843686	Arteriocyte, Inc.	user2@example.com	None	2013-04-30	2018-03-31	2019-03-31	-	-	2025-07-14
Phase I, Arteriocyte Magellan MAR01 Therapy - Compartment Syndrome and Battlefield Trauma	NCT01837264	Arteriocyte, Inc.	user2@example.com	None	2013-01-31	2017-01-31	2018-01-31	-	-	2025-07-14